Delays in treating a patient with an aggressive form of prostate cancer more than likely contributed to his disease advancing ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Joe Biden's battle with stage 4 metastatic prostate cancer has raised new questions about when his illness began, after a ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose ...

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is ...